ChongEA, SvobodaJ, NastaSD, et al.: CD19-directed car t cell therapy (CTL019) for relapsed/refractory diffuse large B-cell and follicular lymphomas: Four year outcomes. Hematol Oncol, 2019; 37(Suppl. S2):137–138.
3.
Van den NesteE, SchmitzN, MounierN, et al.: Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant, 2016; 51:51–57.
4.
MaudeSL, FreyN, ShawPA, et al.: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014; 371:1507–1517.
5.
SantomassoB, BachierC, WestinJ, et al.: The other side of CAR T-cell therapy: Cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book, 2019; 39:433–444.
6.
NeelapuSS, TummalaS, KebriaeiP, et al.: Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol, 2018; 15:47–62.
7.
GreenAK, SaltzLB: Can we afford that CAR? Confronting the effect of novel immunotherapies on future health care costs. J Clin Oncol, 2018; 36:1381–1382.
